Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Prokarium Limited operates within the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions, which are distributed across 2 distinct examiners. This indicates that each active matter is being reviewed by a different official, requiring the company to manage separate prosecution tracks within the same technical field.
The portfolio's activity is concentrated within 1 distinct art unit. The busiest examiner identified is JACKSON-TONGUE, LAKIA J, who is responsible for 1 pending office action. This examiner's workload represents a portion of the total pending matters, as the company navigates the specific requirements of the Biotechnology & Pharmaceuticals sector.
For practitioners, the presence of multiple distinct examiners suggests that prosecution strategies must be individualized, even though the technical focus remains within a single art unit. With JACKSON-TONGUE, LAKIA J handling an active case, the company must address the unique feedback of each assigned examiner to advance its intellectual property goals in this specialized field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18716430 | COMBINATION CANCER THERAPY | DUFFY, PATRICIA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18940334 | CANCER THERAPY WITH LIVE ATTENUATED BACTERIA | JACKSON-TONGUE, LAKIA J | — |
| 18716430 | COMBINATION CANCER THERAPY | DUFFY, PATRICIA ANN | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18940334 | CANCER THERAPY WITH LIVE ATTENUATED BACTERIA | JACKSON-TONGUE, LAKIA J | — | §112DP | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18716430 | COMBINATION CANCER THERAPY | DUFFY, PATRICIA ANN | 1645 | §102§103§112Other | Non-Final OA | — | Pending | Jun 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial